Phase II Iressa + Irradiation Followed by Chemo in NSCLC

Sponsor
AstraZeneca
Study ID
NCT00333294
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Gefitinib — DRUG
  • Radiation therapy — PROCEDURE
  • Cisplatin — DRUG
  • Vinorelbine — DRUG

Study Details

The objective of this study is to determine wether the ZD1839 associated with a radiotherapy, before the beginning of chemotherapy is effective in the treatment of your disease and to evaluate the tolerance of these treatments.

Key Dates

Start date
Sep 30, 2004
Status verified
Dec 2007
Completion
Jan 31, 2006

Study Design

Enrollment
50 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To estimate the objective response rate in patients treated with this drug

Related Studies